Crizotinib activity has been reported in MET-amplified tumors (33), with ongoing studies in EGFR TKI-resistant lung cancer of MET and HGF-targeted agents, such as ficlatuzumab (anti-HGF monoclonal antibody, NCT02034981). This evidence concerns the gene EGFR and lung carcinoma.